Delivery of hydrophilic drugs using sugar glass

Micro/Nano Particles by Talreja, Nitin Kumar & Giri, Jyotsnendu
1 
 
DELIVERY OF HYDROPHILIC DRUGS USING SUGAR GLASS 
MICRO/NANO-PARTICLES 
 
 
NITIN KUMAR TALREJA 
 
 
 
A Dissertation Submitted to 
Indian Institute of Technology Hyderabad 
In Partial Fulfillment of the Requirements for 
The Degree of Master of Technology. 
 
 
 
 
Department of Biomedical Engineering 
 
 
June, 2016 
  
2 
 
 
 
 
3 
 
 
 
4 
 
 
 
 
 
 
 
Acknowledgements 
 
 
   I would like to extend my gratitude to the many people who helped to bring this 
research project to fruition. First, I would like to thank Professor Dr. J. Giri for 
providing me the opportunity of taking my research under his guidance. I am so 
deeply grateful for his help, professionalism, valuable guidance and financial support 
throughout this project and through my entire program of study that I do not have 
enough words to express my deep and sincere appreciation. I would also like to thank 
ENaRm Lab members and Mr. Sunil Yadav for their involvment in the optimization 
for this research project. Without their passionate participation and input, this could 
not have been successfully conducted. 
 
 
 
 
 
5 
 
 
 
 
 
 
List of Figures 
 
2.1.1: Nanoparticles: Overview………………………………………….…………………………………………….24 
2.1.2: Metabolism of PLGA…………………………………………….….………………………...………………..25 
2.8.1: Nanoprecipitation…………………………………………………….…………………………………………..33 
4.3.0: Standard Curve for 5 fluorouracil………………………………..………………………………………….40 
4.3.1: Standard Curve for Metformin……..……………………………….……………………………………….41 
4.3.2: Particle size distribution of metformin nanoparticles prepared by w/o/o…….……………….43 
4.3.1: Particle size distribution of metformin nanoparticles prepared by w/o/w……….……………44 
4.3.2: DLS data of W/O/O Fluorouracil nanoparticles…………………………….…………….…………..45 
4.3.3: DLS data of W/O/W Fluorouracil nanoparticles…………………………………………..………….46 
4.3.4: DLS data of W/O/W with Fluorouracil SgNp nanoparticles………………………………………47 
4.3.5  Sem Image of 5 FU Sgnp at 25.00 kx………………………………………………………………..…….48 
4.5.1  Release profile of 5 FU NP prepared by W/O/W……………………………………………………..51 
4.5.2  Release profile of 5 FU SgNp prepared by W/O/W………………………………………….………52  
4.5.3: Release profile of 5 FU NP 1 % prepared by W/O/W…………………………………….…………52 
6 
 
4.5.4: Release profile of 5 FU SgNP 1 % prepared by W/O/W……………………………….……….….53 
4.5.5: Release profile of 5 FU 5 % SgNp and np made by W/O/W technique………….…………...54 
4.5.6: Release profile of 5 FU 5 % SgNp and np made by W/O/O technique…………..……………55 
4.5.7: Release profile of Metformin Np 1 % prepared by W/O/W technique………….……………..56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
LIST OF TABLES 
 
Table 2.6.1: Strategies to overcome problems in Hydrophilic drug delivery…………………….......30 
Table 4.1.1: Optimum parameters for standard plot………………………………………………………….40 
Table 4.1.1: Optimization of process parameters……………………………………………………………….42 
Table 4.3.1: Data obtained from DLS………………………………………………………..…………………….44 
Table 4.4.1: Comparison of EE of 1 % loading with different loading……………………………..……49 
Table 4.4.2: Encapsulation efficiency of 5 % loading………..……….……………………………………....50 
Table 4.4.3: Encapsulation efficiency of 1 % loading of metformin…….………………………………...50 
 
 
  
8 
 
ABSTRACT 
 
Most of the techniques followed in novel drug delivery systems for encapsulating 
hydrophilic drugs in nanoparticles/Microparticles have some drawbacks such as burst 
release and low encapsulation of drug in polymer particles because of rapid partitioning 
of water soluble drug into the aqueous phase. Double emulsion is one of those 
techniques which has a major limitation of burst release. We hypothesised that applying 
double emulsion technique with Sugar glass nanoparticles could result in better 
encapsulation yield of hydrophilic drug in nano or micro sized particles. Here sugar glass 
nanoparticles are prepared by flash freezing the inverse micellar suspension of drug 
along with other excipeints followed by drying off of the solvents leaving behind the 
surfactant coated nanoparticles which were then encapsulated in the polymer. As a  
model drug we used 5-FU and metformin as a Hydrophilic drug. The new system 
formulated called sugar glass nanoparticle when encapsulated in polymer particles by 
double emulsion technique gave better encapsulation of the drug and the burst release 
from the polymer system unlike conventional technique was also minimised. We have 
also evaluated both the conventional and modified water in oil in oil, double emulsion 
method using sugar glass nano particles as an encapsulant. There was a initial burst 
release of 20-35 % and then it followed sustained release similar to bimodal release 
pattern, whereas in conventional methods, 90 % of burst release was observed. Also the 
size of particles was in range of 300-900 nm. Encapsulation of the drug increased to 
64.33 % when using sugar glass system unlike W/O/W double emulsion method where 
the encapsulation was 4.06 %. It is concluded that this new modified double emulsion 
technique incorporating sugar glass particles of drug is better and advantageous than 
conventional double emulsion technique in terms of size, shape, release profile and % 
encapsulation.
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Chapter 1 
 
INTRODUCTION 
 
1.1 CANCER 
CANCER, One of the leading widespread disease in the world. Patients of cancer are huge in  
number. There are numerous ways in which the disease can be treated but every therapy has a 
drawback. Use of chemotherapy is one of the most commonly used treatments of Cancer. 
Chemotherapy can be defined as the use of drugs or medications to treat a disease. 1 out of 
every 7 deaths in the United States is due to Cancer [cancer.org]. Cancer is a disease of  body 
cells. The cells which are then called cancerous cells become abnormal and keep on dividing and 
forming more cells without control. Normally the cells are expected to divide and reproduce in 
an orderly and controlled manner [63]. The abnormal division and forming of these cells begin to 
form a clump, which is also known as a tumor. These Cancer cells are disorganized because they 
do not differentiate into the tissue of the organ and they never fulfill the function of the organ. 
It is likely that the Cancer cells can affect the other tissues even further if the cells break away 
from the tumor. When these cells separate themselves from the origin, they can be transferred 
around the body through arteries and veins or through the lymphatic system. When these cells 
accumulate in another organ or tissue, it is more than likely that it will start growing there and 
multiply to form another tumor. Cancer cells also produce proteolytic enzymes that attach the 
membrane and allow them to invade the tissue [66] 
 
TYPES OF CANCER-  There are some categories of cancers that begin in specific types  of cells 
and few of them illustrated below. 
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Carcinoma 
Carcinoma is the most common type of cancer. It is formed by epithelial cells; these cells are 
cover the inside and outside surfaces of the body and often have a structure like column. 
Carcinomas are found in different epithelial cell types have specific names, 
Adenocarcinoma 
Cancer which forms in epithelial cells that produce fluids or mucus. Tissues with this type of 
epithelial cell are sometimes known as glandular tissues. Most cancers of the breast, prostate 
and colon are Adenocarcinoma. 
Basal cell carcinoma is a cancer which begins in the lower last layer; also called as basal layer 
of the epidermis( outer layer of skin ). 
Squamous cell carcinoma is a cancer which that originate in cells that are epithelial in origin 
and lie just below the outer surface of the skin. Squamous cells form lining for many other 
organs, such as the stomach, bladder, lungs, intestines and kidneys. Squamous cells look fl at, 
like fish scales, when viewed under a microscope. Squamous cell carcinomas are sometimes 
known as epidermoid carcinomas . 
Transitional cell carcinoma is a cancer which forms in a type of epithelial tissue which is called 
transitional epithelium, or urothelium. This tissue is made up of many layers of epithelial cells 
that can get bigger and smaller, is found in the linings of the bladder, ureters, and part of the 
kidneys (renal pelvis), and other organs. Some cancers of the bladder, kidneys and ureters are 
transitional cell carcinomas. 
Sarcoma: 
Sarcoma is a cancer which is formed in bone and soft tissues, including muscle, blood vessels, 
fat, lymph vessels, and fibrous tissue. 
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Osteosarcoma is the most common type of cancer. It is the cancer of bone. The most common 
types of soft tissue sarcoma are Kaposi sarcoma, malignant fibrous histiocytoma, 
leiomyosarcoma, liposarcoma and dermatofibrosarcoma protuberans . 
Leukemia: 
Cancers which are begun in the blood-forming tissue of the bone marrow are known as 
leukemias. Solid tumors are not formed in this cancer type. Instead, large numbers of abnormal 
white blood cells (leukemia cells and leukemic blast cells) build up in the blood and bone 
marrow, crowding out normal blood cells. The low level of normal blood cells lead to lower 
oxygen level in the body and problems arises in controlling bleeding and fight. 
 
Lymphoma: 
Lymphoma begins in lymphocytes. These are disease-fighting white blood cells which are part of 
the immune system. In lymphoma, mutated lymphocytes accumulate in lymph nodes and lymph 
vessels, as well as in other organs. 
Multiple Myeloma: 
Multiple myeloma is a cancer that starts from the plasma cells; these are kind of immune cells. 
The abnormal plasma cells, known as myeloma cells, build up in the bone marrow and form 
tumor like masses in bones. Multiple myeloma is also known as plasma cell myeloma and Kahler 
disease. 
 
 
CAUSES OF CANCER- Cancer is a tangled group of diseases with as many possible causes. 
These are lifestyle factors such as diet, and physical activity; tobacco use; Few types of 
infections; epigenetic factors and exposure of body to different types of chemicals, carcinogens 
and radiation. 
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Chemical carcinogens 
It may be defined as something (chemical, radiation, etc) which can harm or damage a cell and 
make it to turn into a cancerous cell. The general rule says, the more the exposure to a 
carcinogen, the greater the risk. Some of the Examples are: 
 Tobacco smoking leads to cancer of the lung, mouth, oesophagus, throat, pancreas  
and bladder. A prevelant notion is that smoking causes about 1 in 5 of common cancers. 
About 1 in 8 death occurs because of tobbaco smoking induced lung cancer. The more you 
smoke, the greater you become prone to Cancer. 
 Chemicals in the laboratories such as asbestos, mercury, benzene, formaldehyde, etc. If you 
have worked with these without protective measures you have an increased risk of 
developing certain cancers. 
Age 
The older you become, the chances are that you will develop a cancer. This is probably due to 
the persistence of damage to cells over time. Also, the body's defences and resistance against 
abnormal cells may become less good  as we grow old. For example, the capability to repair 
damaged cells, and the immune system which  destroys abnormal cells, may becomes negligent 
with age. So, eventually one damaged cell may manage to survive and multiply out of control 
into a cancer. Most cancers develop in aged people. [64] 
Lifestyle factors 
We are what we eat. Diet and other lifestyle factors can increase or decrease the risk of 
developing cancer. For example: 
 If we eat fruits and vegetables you have a reduced risk of developing these cancers. The 
specefic way in which they protect us against cancer is not fully derived. These foods are 
rich in vitamins and minerals, and also contain chemicals called antioxidants. They may 
protect against carcinogens that get into the body. 
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 Eating too much fatty food possibly increases the risk of developing certain cancers. 
 The risk of developing certain cancers is increased by obesity, lack of regular 
exercise, drinking too much alcohol and eating a lot of red meat. [65] 
Some examples of studies looking at lifestyle factors and cancer: 
A large review of data (Parkin et al) found that about 4 in 10 cancers diagnosed in the UK each 
year - over 130,000 in total - are caused by avoidable lifestyle factors and choices including 
smoking, alcohol, weight and diet. Quote from lead author Professor Parkin ... "Many people 
believe cancer is down to fate or 'in the genes' and that it is  the luck of the draw whether they 
get it. Looking at all the evidence, it's true that around 55% of all cancers are caused by things 
we mostly have the power to change." [66] 
One more research study (Kirkegaard et al) followed up over 56,000 people for 10 years. It 
looked at lifestyle factors and rates of cancer. The study concluded that by following those 
suggestions on keeping physically active, keeping body weight in check, not smoking, drinking 
alcohol in moderation and having a healthy diet, the risk of developing bowel cancer could be 
reduced by as much as 24%. But, the study found that even improving in some of these lifestyle 
factors had some reduction in risk. [66] 
A study which followed up 363,978 people found that about 15 in 100 of all cancers in men and 
about 5 in 100 in women in Europe are caused by consuming alcohol. Most cancer cases were 
observed with people who consumed higher than the recommended toxic limits. But the survey 
also found that even drinking more than three units a day for men and more than one unit a 
day for women  increased the risk of developing certain cancers.[66] 
A study that followed up over 10,00,000 people in the USA suggests that cutting the amount of 
red meat in most people's diets to 42 g per day (equal to about one large steak a week) could 
significantly reduce the incidence of certain cancers. [66] 
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Radiation 
Radiation is a carcinogen. if we are exposed to radioactive materials and nuclear rays, this can 
increase the risk of myeloma and other cancers. Too much sun exposure and sunburn /UV rays 
increase your risk of developing skin cancer. The more the intensity of radiation, the greater the 
risk of developing cancer. But the risk from small doses, such as from a single X-ray test, is very 
small. [68] 
Infection 
Some germs (viruses and bacteria) are linked to certain cancers. For example, people with 
persistent infection with the hepatitis B virus or the hepatitis C virus have an increased risk of 
developing cancer of the liver. Another instance is the relation between the human papilloma 
virus (HPV) and cervical cancer. Most women who develop cervical cancer have been infected 
with a strain  of HPV at some point in their life. Another link is between the H.pylori, a germ 
(bacterium) to stomach cancer. 
One research study estimated that about one in five cancers - 2.5 million a year globally - are 
caused by treatable or curable infections. They estimated that four infections - HPV, H. pylori, 
and hepatitis B and C viruses - accounted for 2 million cases of cervical, stomach and liver 
cancers in 2007-8. Most of these were in the developing countries. Initiatives such as 
immunization against HPV and hepatitis B are helping to combat these infections. But, most 
viruses and viral infections are not linked to cancer. [66] 
Immune system 
People with a poor immune system have an increased risk of developing certain cancers. For 
example  people on immunosuppressive therapy. [67] 
Genetic make-up 
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Some cancers have a strong genetic link. For example, in certain childhood cancers the 
abnormal gene or genes which may trigger a cell to become abnormal and cancerous are 
inherited. Other types of cancer may have some genetic factor which is less clear-cut. It may be 
that in some people their genetic make-up means that they are less resistant to the effect of 
carcinogens or other factors such as diet. 
Most cancers are probably due to a multitude of factors. Not everyone who has contact with a 
potential cancer-causing substance (carcinogen) or has an unhealthy lifestyle will develop cancer. 
For example, not all smokers develop cancer of the lung. In fact, we are all probably exposed to 
low doses of carcinogens a lot of the time. 
The body has certain mechanisms which may protect us from developing cancer. For example, it 
is thought that many cells which are damaged by carcinogens can repair themselves. Also, the 
body's immune system may be able to destroy some types of abnormal cells before they multiply 
into a tumor. Perhaps one carcinogen may only damage one gene, and two or more genes may 
need to be damaged or altered to trigger the cells to multiply out of control. In many cases it is 
likely that there is a combination of factors (such as genetic makeup, exposure to a carcinogen, 
age, diet, the state of your immune system, etc) which turns oncogenes to active state. These 
may play an active part in initiating the signal to a cell to become abnormal, and allowing it to 
multiply uncontrollably into a cancer. [American society of cancer]  
There are more than 100 types of cancer, including, skin cancer, lung cancer, colon cancer, 
prostate cancer, breast cancer and lymphoma. Symptoms vary depending on the type. 
Oral chemotherapy is usually taken in the form of a tablet or capsule. Now these pills have 
many side effects which generally are categorized as  adverse effects. These ill effects include  
Fatigue, pain, (Headache, Muscle pain, stomach pain, pain from damage of nerve), burning 
sensation, hairfall, mouth and throat sores, mucositis. Diarrohea, constipation, irregular bowel 
syndrome an some nervous system effects are common side effects of cancer drugs. These drugs 
also cause trouble thinking clearly and concentrating after chemotherapy. This is often referred 
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as chemo brain by cancer survivors. Appetite loss is also observed in almost all the patients of 
cancer chemotherapy.  
 
 
DRUGS FOR CANCER- Serendipity led to the use of nitrogen mustard to kill unwanted cells 
and began the era for development of cytotoxic drugs to kill cancer cells. Depending on the 
type, location and severity of cancer, chemotherapy for a specefic individual after translational 
research can be modified. Chemotherapy includes vast number of drugs and there use depends 
on the type of cancer and best suited mechanism to stop reproduction of cell. To further define 
different mechanisms of drug, let us look at some examples. 
Methotrexate and vinca alkaloids are called anti metabolites. They kill dividing cells only during 
a specific part or parts of the cell cycle which is known as S phase and M phase. These drug 
inhibit the spindle formation and alignment of chromosomes. [69,71] 
Alkylating agents and platinum derivatives are toxic to both tumor and normal cells whether 
they are in the proliferating or resting phase. They have a linear dose–response curve; that is, 
the greater the dose of the drug, the greater the fractional cell  kill. And thus this is leads to 
death of normal cells as well. [70] 
Oxaliplatin belongs to a new class of platinum agent. It contains a platinum atom complexed 
with oxalate. It forms reactive platinum complexes that are believed to inhibit DNA synthesis 
by forming interstrand and intrastrand cross -linking of DNA molecules [72] 
Histone deacetylase (HDAC) inhibitors- These are a relatively new class of anti-cancer agents 
that play potential roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, 
and cell cycle arrest in cancer cells. [63] 
Pyrimidine analogues- These drugs resemble pyrimidine molecules and work by either inhibiting 
the synthesis of nucleic acids (e.g. fluorouracil, inhibiting enzymes involved in DNA synthesis 
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(e.g. cytarabine, which inhibits DNA polymerase) or by becoming incorporated into DNA (e.g. 
gemcitabine), interfering with DNA synthesis and resulting in cell death. 
 
1.2.  5-Fluorouracil  
 
Instigated as a rationally synthesised anticancer agent 40 years ago, continues  to be used in the 
prophylaxis of various common malignancies including cancer of the rectum, colon, skin and 
breast. This drug is an analogue of uracil; pyrimidine ring analogue, and is metabolised by the 
same metabolic pathways as that of uracil. Although several potential sites of antitumour 
activity have been discovered. The picture still remains blurred as, the meticulous mechanism of 
action and the extent to which each of these sites contributes to tumour or host cell toxicity is 
very unclear. 
Various assay methods are available to quantify 5-fluorouracil in serum, plasma and other 
biological fluids. Unfortunately, there is no substantial proof that plasma drug concentrations 
can predict antitumour effect or host cell toxicity. The recent establishment of clinically useful 
pharmacodynamic assays provides a far better alternative to plasma drug concentrations, since 
these assays allow the detection of active metabolites of 5-fluorouracil in biopsied tumour or 
normal tissue. 
5-Fluorouracil has a poor absorption after oral administration, with unpredictable 
bioavailability. The parenteral preparation is the major dosage form, used intravenously (bolus 
or continuous infusion). A liitle while back, studies have demonstrated the pharmacokinetic 
rationale and clinical feasibility of hepatic arterial infusion and intraperitoneal administration of 
5-fluorouracil. In addition, 5-fluorouracil continues to be used in topical preparations for the 
treatment of malignant skin cancers. 
Following parenteral administration of 5-fluorouracil, there is speedy distribution of the drug 
and rapid elimination with an apparent half-life of 8 to 20 minutes approx. The rapid 
elimination is because of the swift catabolism of 5-fluorouracil in the liver. 
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As in case of all drugs, precautions should be taken in administering 5-fluorouracil in various 
neoplastic states. In general, however, there are no set recommendations for dose adjustment in 
the presence of renal or hepatic dysfunction. Drug interactions continue to be described with 
other antineoplastic drugs, as well as with other classes of agents.[74] 
 
As we can clearly conclude from the illustrated examples, that most of the anticancer drugs are 
harmful for normal cells of the body. As a preventive measure to this side effect, we can reduce 
the dose of the drug, but that will lead to inadequate pharmacological effect because drug won't 
reach to the desired concentration. There should be a solution that though lesser amount of 
drug is ingested, it exerts equal therapeutic effect. and this is possible by making the drug reach 
specefic site where cancer cells are present. Imagine a situation where there are minimal side 
effects, now we can think of what are the ways we can minimize these side effects. These are 
directly proportional to amount of drug being ingested in our body.  If we can treat a particular 
disease at a low dose then it is beneficial in both the ways, i.e. it reduces the side effects, lowers 
the incidence of drug interaction and thereby reducing the cost of the medicine. Unfortunately 
due to lack of specification and solubility of drug molecules, patients have to take high doses of 
the drug to achieve the expected therapeutic effects for the prophylaxis of diseases. The 
problems in conventional dosage form are not limited to as stated above, we do observe 
repeated ingestion of drugs which is not patient friendly. To solve/ overcome these problems, 
We need a novel drug delivery system.  
 
1.3 Novel Drug Delivery System  
The process by which a drug is delivered can have a significant effect on its therapeutic effect. 
Some drugs have an optimum therapeutic window within which maximum benefit is derived, 
and concentrations above or below this range can induce adverse effects or produce no benefits 
at all. Furthermore, the very slow progress in the prophylaxis of the treatment of chronic 
diseases, has suggested a growing need for a multidisciplinary approach to the delivery of 
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therapeutics to specefic sites. And this led to innovative ideas on regulating the 
pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and 
pharmacology of drugs were generated. These new strategies, were called drug delivery systems 
(DDS) and are based on multidisciplinary approaches that combine polymer science, 
pharmaceutics, bioconjugate chemistry, and molecular biology [75]. There are 
various drug carriers and formulations present in the pharmaceuticals, which are used for the 
delivery of therapeutic agents to the targeted site, at the same time maintaining the adjunct 
dose levels by behaving as controlled release and sustained release systems etc. [1]. One such 
emerging technique is the use of nanoparticles to deliver drugs at target site. These 
nanoparticles are used as widely in the field of diagnosis, target drug delivery, bio-sensing, 
cellular uptake, etc., in the bio-medical field. There has been a lot of research on the delivery of 
drugs using different carriers like nanocapsules, nanoparticles and microsphere. These 
nanoparticles were evaluated to deliver the drugs and maintain the concentration in a controlled 
manner. Controlled drug delivery systems (DDS) have several advantages compared to the 
conventional forms of drugs.[] A drug reaches only to the place of action, unlike conventional 
forms where it is distributed in whole body, hence its influence on vital tissues and undesirable 
side effects can be minimized. Stockpiling of therapeutic agents in the target site increases as a 
result of which, the required doses of drugs are lower. This modern form of therapy is especially 
important when there is a confusion between the dose or the concentration of a drug and its 
therapeutic results or toxic effects. Cell-specific delivery can be achieved by 
attaching/incorporating drugs in specially designed carriers. Various nanostructures, including 
liposomes, polymers, dendrimers, complex structures of silicon and carbon, and magnetic 
nanoparticles, have been tested as carriers in drug delivery systems.[2]  
 
For over 30 years, scientists have appreciated the prospective benefits of nanomedicine and 
technology in providing huge improvements in drug delivery and drug targeting. Improving 
delivery techniques that has negligible toxicity and improved therapeutic efficacy offers great 
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potential advantages to patients, and opens up opportunities for new markets in pharmaceutical 
industry. Other approaches to drug delivery are focused on crossing blood brain barrier; a 
physical barrier to most of the foreign agents in the body, in order to better target the drug and 
improve its effectiveness; or on finding alternative and better routes for the delivery of drugs 
other than via the gastro-intestinal tract, which generally leads to first pass metabolism. 
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Chapter 2 
 
LITERATURE REVIEW 
 
The literature review covers all the information obtained which is relevant to my project. It 
covers the Types of nanoparticle Systems, methods to prepare nanoparticles, examples of system 
encapsulating hydrophobic and hydrophilic drugs and relevant procedures to characterize 
nanoparticles.   
 
2.1 TYPES OF NANOPARTICLE SYSTEM 
Nanoparticles can be made from either metals or polymers and also from other synthetic 
compounds. In general, nanoparticles used in the field of biotechnology ranges in between 20 
and 520 nm, seldom exceeding 800 nm. The nano size of these particles facili tates all 
communications with biomolecules on the surface of cell and within the cells in way that results 
in and can be designated to various physiochemical and biochemical properties of these cells [7]. 
Similarly, its huge application in drug delivery system and noninvasive bioimaging has 
discovered various advantages over conventional pharmaceutical agents [7]  
Metallic Nanoparticles-: 
As the name suggests, these are made of metals. Metallic nanoparticles have captivated 
researchers for over a century and are now are widely utilized in biomedical sciences and 
engineering. They are a focus of interest because of their huge potential in nanotechnology. 
Today these materials can be synthesized and modified with various chemical functional groups 
which allow them to be conjugated with antibodies, ligands, and drugs of interest and thus 
24 
 
opening a wide range of potential applications in biotechnology, magnetic separation, and 
preconcentration of target analytes, targeted drug delivery, and vehicles for gene and drug 
delivery and more importantly diagnostic imaging.  
Polymeric Nanoparticles-:  
Polymer nanoparticles have attracted the interest of many research groups and have been 
utilized in an increasing number of fields during the last decades. Generally, two main strategies 
are employed for their preparation: the dispersion of preformed polymers and the polymerization 
of monomers. [4] Many polymers now have been discovered which are biodegradable, and hence 
the gradual degradation results in the controlled release delivery of drugs, also the toxicity 
associated with the external material is minimised as compared to Metallic nanoparticles which 
are generally toxic [5]  
The below stated picture represents the toxicity of nanoparticles and also illustrates the     
possible mechanism of toxicities associated with these metallic nanoparticles. 
This is the reason polymeric nanoparticles have gained much of attention in drug delivery. Also 
another property to be stated is that of biocompatibility of polymers like PLGA.  
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PLGA or poly(lactic-co-glycolic acid) is a copolymer which is used in a host of Food and Drug 
Administration (FDA) approved therapeutic devices, owing to its biodegradability and 
biocompatibility. (Wiki). Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully 
developed biodegradable polymers. Among the different polymers developed to formulate 
polymeric nanoparticles, PLGA has attracted considerable attention due to its attractive 
properties:  
 Biodegradability and biocompatibility. 
 FDA and European Medicine Agency approval in drug delivery systems for parenteral 
administration,  
 Well described formulations and methods of production adapted to various types of 
drugs e.g. hydrophilic or hydrophobic small molecules or macromolecules, 
 Protection of drug from degradation,  
Figure 2.1.1: Nanoparticles:  Overview 
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 Possibility of sustained release,  
 Possibility to modify surface properties to provide stealthness and/or better interaction 
with biological materials.  
 Possibility to target nanoparticles to specific organs or cells.[6]  
Polymers can also be used to coat other types of nanoparticles. Polyethylene glycol (PEG) is a 
hydrophilic polymer that has been used to coat the surface of nanoparticles, which allows them 
to avoid clearance by the reticuloendothelial system [8]. The degradation time can vary from 
several months to several years, depending on the molecular weight and copolymer ratio [9]  and 
[10] The forms of PLGA are usually identified by the monomers ratio used. For example, PLGA 
50:50 identifies a copolymer whose composition is 50% lactic acid and 50% glycolic acid. 
Poly(lactic acid) (PLA) has also been used to a lesser extent than PLGA due to the lower 
degradation rate. 
 
 
METABOLISM OF PLGA 
 
 
 
Figure 2.1.2: Metabolism of PLGA 
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2.2 METHODS TO PREPARE NANOPARTICLES 
There are several methods to prepare nanoparticles. Depending on the method of preparation, 
the structural organization may differ.  
The drug is either entrapped inside the core of a “nanocapsule” as well as entrapped in or 
adsorbed on the surface of a matrix “nanosphere”. 
The most common technique used for the preparation of PLGA nanoparticles is the 
emulsification-solvent evaporation technique. This technique allows the encapsulation of 
hydrophobic drugs and consists in dissolving the polymer and the compound in an organic 
solvent (e.g., dichloromethane). The emulsion oil (O) in water (W) i.e. O/W is prepared by 
adding water and a surfactant (e.g., polysorbate-80, poloxamer-188) to the polymer solution. 
The nanosized droplets are induced by sonication or homogenization. The solvent is then 
evaporated or extracted and the nanoparticles collected after centrifugation [1]  and [16].  
A modification of this technique, the double emulsion W/O/W, was used to encapsulate 
hydrophilic drugs, such as peptides, proteins and nucleic acids. Nanoparticles can also be 
prepared by the nanoprecipitation method which is also known as the interfacial deposition 
method [17]. Briefly, the drug and the polymer are dissolved in an organic solvent (such as 
acetone) and added drop wise to water. The organic solvent is allowed to evaporate and the 
pellets formed are collected after centrifugation. Other techniques exist such as the spray-drying 
method [1]. Drug loading into nanoparticles is achieved by two methods: (i) the incorporation of 
the drug during the nanoparticles production and (ii) the adsorption of the drug on 
nanoparticles after their production. 
Solvent evaporation was the first method developed to prepare PNPs from a preformed 
polymer [25]. Although originally proposed by polymer chemists, These proccess are followed in 
pharmaceutical technology where biodegradable polymers have been applied in the production of 
drugs [26]. In this method, polymer solutions are prepared in volatile solvents and emulsions are 
formulated. In the past, Organic solvents like dichloromethane and chloroform were widely used, 
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but are now replaced with ethyl acetate which is less toxic. The emulsion thus formed is 
converted into a nanoparticle suspension after the evaporation of solvent, and this solvent 
actually diffuses through the continuous phase of the emulsion [27] and [28]. 
Nanoprecipitation-- The nanoprecipitation method was developed by Fessi et al. [50] for the 
preparation of PNP. It is also called as solvent displacement method. The basic principle of  this 
technique is based on the interfacial deposition of a polymer after displacement of a semipolar 
solvent, miscible with water, from a lipophilic solution. Rapid diffusion of the solvent into non-
solvent phase results in the decrease of interfacial tension between the two phases, which 
increases the surface area and leads to the formation of small droplets of organic 
solvent [40] and [41]. Nanoprecipitation system consists of three basic components: the polymer 
(synthetic, semi synthetic or natural), the polymer solvent and the non-solvent of the polymer. 
Organic solvent (i.e., ethanol, acetone, hexane, methylene chloride or dioxane) which is miscible 
in water and easy to remove by evaporation is chosen as polymer solvent. Due to this reason, 
acetone is the most frequently employed polymer solvent in this method [50], [42] and [43].  
Sometimes, it consists of binary solvent blends, acetone with small amount of water [44], blends 
of acetone with ethanol [45], [46] and [47] and methanol [48]. On the other hand, the non-solvent 
phase consisting of a non-solvent or a mixture of non-solvents is supplemented with one or more 
naturally occurring or synthetic surfactants 
 
 
2.3 EXAMPLES OF SYSTEM ENCAPSULATING HYDROPHOBIC DRUGS 
PLGA nanoparticles loaded with hydrophobic, poorly soluble drugs are most commonly 
formulated by nanoprecipitation. Drug release and effective response of PLGA nanoparticles are 
influenced by  
(i) the surface modification, (ii) the method of preparation,  
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(iii) the particle size,  
(iv) the molecular weight of the encapsulated drug and 
(v) the ratio of lactide to glycolide moieties  [3].  
PLGA nanoparticles are described in the literature as effective nanocarriers for the 
encapsulation of various anti-cancer agents such as paclitaxel [19], 9-nitrocamptothecin [20], 
cisplatin [21], etc. but also for the encapsulation of various drugs such as haloperidol [22], 
estradiol [23], etc. Other systems include the microspheres and Nanodots. 
 
2.4 EXAMPLES OF SYSTEM ENCAPSULATING HYDROPHILIC DRUGS  
1. Valproic acid- Hydrogel nanoparticles [14] 
2. Isoniazid- Inhalable chitosan nanoparticles [30] 
3. Allopurinol- polycyanoacrylate nanoparticles [31] 
4. lamivudine- Formulation and evaluation of ethosomes for transdermal delivery 
 
2.5 CHALLENGES TO THE ENCAPSULATION AND DELIVERY OF HYDROPHILIC   
DRUGS 
The results of the encapsulation efficiency analysis demonstrated that more lipophilic drugs, 
such as cyclosporin and indomethacin, do not suffer from the problems of drug leakage to the 
external medium, resulting in improved drug content in the nanoparticles.  
In spite of the fact that valproic acid is a liquid that is very sparingly soluble in water, very low 
encapsulation efficiency was obtained. Ketoprofen, a drug sparingly soluble in water, 
demonstrated intermediate values of encapsulation that were well correlated with its 
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intermediate lipophilicity. More hydrophilic drugs, such as vancomycin and phenobarbital, were 
poorly encapsulated in PLGA nanoparticles. [11] Hydrophilic drug encapsulation/delivery is 
complex when the procedure called double emulsion technique is followed, the reason to the 
complexity of latter can be in short explained as the drug inside the polymer suspension has 
high affinity to external phase solvent, i.e. is the aqueous phase and as a result the 
encapsulation efficiency is less. The major problems are 
1. Low encapsulation efficiency 
2. Burst release 
3. Loading capacity 
4. Drug loss due to inefficient solvent system 
 
2.6 INITIATIVES TAKEN TO SOLVE SUCH PROBLEMS 
Hydrophilic drug delivery still remains a challenge; this either being attributed to the fragility 
and poor cellular penetration of macromolecules, or to the unsuitable pharmacokinetics and 
toxicity of small drugs, for instance anticancer agents. By offering more favorable 
pharmacokinetics and protection of the drug, encapsulation in polymer nanoparticles constitutes 
an attractive possibility to overcome these problems. [12] Refer table 2.6.1 
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Table 2.6.1 Strategies to overcome problems in Hydrophilic drug delivery 
DRUG PREPARATION 
METHOD 
STRATEGY RESULT REFERE
NCE 
5-FU Monomer 
emulsion 
polymerisation 
pH increase Enhancement of the 
polymerisation rate 
[32] 
Vasopressin 
PLA 
 
 
Emulsion-solvent 
evaporation 
Reverse micelles Enhancement of drug 
solubility in the 
polymer network 
[33] 
 
doxorubicin 
hydrochloride 
(CHITOSAN) 
Chitosan ionic 
gelation 
Polyanion 
(dextran 
sulphate) 
2-fold increase of EE [34] 
Gemcitabine Redox radical 
emulsion 
polymerisation 
 
Chitosan/Ion 
pair formation 
Ionic interaction 
between SiRNA and 
chitosan and increase of 
nanoparticle loading 
 
[36] 
   
 
 
Aqueous-core nanocapsules-: 
Nanocapsules with an aqueous core are a result of relatively recent technology developed for 
encapsulating hydrophilic molecules. Aqueous-core nanocapsules (ACN) consist of nanoparticles 
exhibiting a core shell structure, the core being composed of liquid water, generally surrounded 
by a thin polymer shell. The advantages of such a structure for encapsulating hydrophilic 
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molecules lie firstly in the high drug encapsulation efficiency due to the optimised drug 
solubility in the nanoparticle core and low polymer content compared to polymer nanospheres. 
Secondly, for entrapment in polymer nanoparticles; since the drug is ‘protected’ within the 
nanocapsules, tissue irritation at the administration site as well as the burst effect are reduced, 
and the drug remains protected against degradation [38] 
 
2.7. SUGAR GLASS NANOPARTICLES  
This was one of the best initiated research for the delivery of Hydrophilic molecules, either 
protein or drugs; and had a good encapsulation efficiency along with a controlled release profile, 
better storage possibilities of the formulation i.e., the storage activity loss was less. The author 
here tried it for the delivery of  protiens and also followed the procedure of double emulsion, 
and achieved a very high encapsulation efficiency for protiens. 
 
RESULTS IN SGNP TECHNIQUE  
The post encapsulation recovery of proteins activity after incubation into polycaprolactone 
(PCL) + chloroform solution compared to a common approach where HRP was added from 
buffer was very high. Results for the protective performance of the SGnPs with respect to 
process related stresses shows that the SGnP system provide excellent protection from array of 
non-aqueous solvents, showing excellent sustained release profiles (30% during 30 days) without 
significant burst release (only 8 to 11 % release on day 1) from nanofiber or gas -foamed scaffolds 
made of PCL and induced bone formation within 30 days compared to scaffold with BMP2 
encapsulated by conventional technique. This system also offers excellent encapsulation 
efficiency (≈  100%) of the protein incorporated into the polymer scaffold, with only minor 
activity loss (< 5%) at the encapsulation step [35] 
 
33 
 
 
Reviewing the literature we can conclude that there are 2 specific problems to be solved with 
respect to hydrophilic drug delivery and thus we aim at a developing a system with minimal 
burst release and higher encapsulation efficiency, and this can be summarized in 3 objectives 
given below 
1. Optimization of process parameters and selection of the most preferred technique. 
2. Development of sugar glass nanoparticles and encapsulation of latter into the polymer so as 
to achieve higher encapsulation and lower burst release. 
3. Physical and biological characterization/evaluation of the system. 
 
2.8 Encapsulation of Hydrophilic drugs- 
It is not possible with single emulsion solvent evaporation method. So a modified technique 
called double emulsion is to be followed; A coin has 2 sides so do all techniques have pros and 
cons. The main aim is to achieve higher encapsulation efficiency and a controlled release profile. 
Talking about the latter, the release is attributed to the rate of degradation of Plga polymer. 
Even if polymer release is achieved, there are still chances of burst release in the formulation. 
Now for the encapsulation; the drug incorporated should not release from the polymer system 
into the external solvent and the possibility for such release is very high if we use a aqueous 
solvent; but using a less aqueous solvent can solve this problem; another option left is to use 
some different techniques to make these Nanoparticles for example if we follow a method called 
Oil in Oil emulsion technique which excludes the use of water. However this technique has not 
been tested on plga.  
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Another method of interest includes the non aqueous encapsulation of drug substance, 
illustrated in the paper; Non-aqueous encapsulation of excipient-stabilized spray-freeze dried 
BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. [76] 
Modified nanoprecipitation method- 
 
 
 
 
 
In summary, we aim to create a robust and biocompatible nanoparticle platform that can 
selectively deliver a chemotherapeutic agent to the tumor site. Nanoparticle drug delivery is 
advantageous when compared to direct delivery of the drug in that it can prolong the timeframe 
of the effectiveness of the drug and can be directed to the tumor site via the EPR effect and 
selective targeting. PLGA nanoparticles are advantageous in that they are biocompatible and 
nontoxic.  
Figure 2.8.1 Nanoprecipitation[76] 
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Chapter 3 
MATERIALS AND METHOD 
 
3.1 MATERIALS 
PLGA (50:50), DCM, 5 FU (hychem), PVA; high molecular wieght, Trehalose dihydrate, 
metformin (gift sample), liquid nitrogen (bought from Sangareddy), (Isoctane, AOT, tween 20, 
span 80, paraffin oil, n hexane),General solvents were of analytical grade and were procured 
from Hychem laboratories 
3.2 EXPERIMENTATION  
This project has been carried out in steps for which the methods are described. 
1.  Optimization of process parameters for water in oil in water emulsion method.  
2. Preparation of polymer nano particles of 5 FU (different loading), by O/O and W/O method. 
3. Characterization of nano particles for the particle size, EE and release, surface morphology. 
4. Preparation of sugar glass nano particles by flash freezing.  
5. Encapsulation of prepared SGnp's into polymer and further characterization of the same as 
above.  
3.2.1 STANDARD PLOT FOR DRUGS 
The standard plot for drugs was made by using UV Spectrophotometer. The standard solution 
was prepared by dissolving 10 mg of drug in 100 mL pbs (ph 7.4). Further dilutions were done 
to make a note of readings at different concentrations. The resulting graph was extrapolated. 
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3.2. PREPARATION OF PLGA NANOPARTICLES 
PLGA nanoparticles have been mostly prepared by double emulsion–solvent diffusion [46], 
solvent emulsion–evaporation [36], interfacial deposition [42] and nano precipitation method [47]  
Generally in emulsiﬁcation – diffusion method, the polymer to be used is dissolved in organic 
solvents (PC, BA, EtAc, MEK, etc.), poured and homogenised in aqueous phase having 
stabilizer and subsequently emulsiﬁed by homogenizer. In solvent evaporation method, the 
polymers are dissolved in volatile organic solvent (CHCl3, EtAc, acetone, DCM, etc.) and 
injected into aqueous phase on stirring (addition of emulsiﬁer/stabilizer is optional) and 
sonicated. Interfacial deposition methods have been used for the formation of both nanocapsule 
and nanospheres. The nanoparticles are synthesized in the interfacial layer of water and organic 
solvent (water Immiscible). At last the nanoparticles are recovered by centrifugation.  
BY W/O/W METHOD 
The double emulsion solvent evaporation method was employed for the formation of drug-
encapsulated PLGA Nanoparticles, similar to previously described. Brieﬂy, fluorouracil (or 5-
FU) was dissolved in water. Polymer was likewise dissolved in DCM and mixed with the drug 
solution and homogenised at 12 k for 1 minute to form a Primary emulsion. NPs were formed 
by adding the drug–polymer solution/ primary emulsion to PVA (Self emulsifying agent; Here 
acting as an external phase for the secondary emulsion) and homogenizing at 18 k for 5 mins. 
The resulting NP emulsion was allowed to stir uncovered for 3h at room temperature for the 
evaporation of organic solvent. The emulsion is converted into a nanoparticle suspension on 
evaporation of the solvent for the polymer, which is allowed to diffuse through the continuous 
phase of the emulsion. Nanoparticles were recovered by centrifugation (12 k rpm for 10 mins). 
The PLGA–NPs were resuspended, washed with water and collected. Further proccess includes 
the resuspension of formed NPs in sufficient amount of water, freezing at -800 C. The freezed 
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Nps were lyophilised in (Instrumrent) and then were characterised for aforementioned 
paramenters. 
BY WATER IN OIL IN OIL EMULSION METHOD 
As this is also a double emulsion method, Two emulsions were prepared. The primary emulsion 
was prepared by homogenizing the aqueous phase containg drug with the polymer solution 
(polymer dissolved in dcm). The homogenization was done for 1 min at 20 k and then this 
primary emulsion was injected drop wise into liquid parrafinn to prepare the final emulsion. 
This is further homogenised for 5 minutes to form a stable emulsion. The is now called 
secondary emulsion. The secondary emulsion is kept on stirring for the solvent evaporation for 3 
hrs. n hexane was added at regular intervals for particle hardening. After stirring the emulsion 
is centrifuged at 12 k rpm for 5 minutes to recover the particles. These particles were washed 
with n hexane and then were resuspended in the same. The n hexane was allowed to evaporate 
and particles were collected. 
 
 
3.3. PREPARATION OF SUGAR GLASS NANOPARTICLES 
Sgnp were prepared by inverse micelles of AOT in isooctane in a 50 mL centrifuge tube. 
Aqueous phase of 0.4 mL to 0.6 mL containing the drug and other excipients (trehalose and 
tween 20) was then added. This mixture was vortexed for 3 mins to obtain a clear suspension. 
The pH of aqueous phase was adjusted to give maximum drug solubility and stability at room 
temperature. The inverse micelle suspension was flash frozen by injecting it into a vial 
containing liquid nitrogen. The vial with the frozen particles and iso ocatne was lyopjilised to 
evaporate water and iso octane. After this process the particles were recovered by centrifugation 
and then were washed with iso osctane. The washing was repeated for 3 times to remove the 
remaining AOT. Particles were resuspended in Iso octane and stored at -800 C for future use. 
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ENCAPSULATION OF SGNPS by BOTH THE METHODS 
The prepared sgnps were analysed for the drug content and accordingly specefied amount of 
sgnps were mixed with the polymer solution and vortexed for 1 min to get a stable emulsion. As 
this method involves the mixing of solid particles in the polymer solution, this is also called as 
S/O/O or S/O/W depending upon the final phase of the double emulsion. The procedure 
followed is same as previously described. 
 
3.4. CHARACTERIZATION 
1. SIZE ANALYSES-  
i) BY MICROSCOPY- Slide was prepared by suspending particles in water and then was 
viewed under microscope. The morphology was observed and needful  calculations were done to 
measure the size of particles. 
ii) BY DLS- The mean particle size, size distribution and polydispersity index were determined 
by dynamic light scattering (BIC 90 plus, Brookhaven Instruments Corp.). The analyses were 
performed at a scattering angle of 90° and a temperature of 25 °C. For each sample, the mean 
particle diameter, polydispersity and standard deviation for ten determinations were calculated. 
The sample was prepared by suspending 5 mg of polymer particles in water and s onicating at  
for 1 min. 
2. ENCAPSULATION EFFICIENCY-  
3 replicates of the prepared sample were prepared by dissolving 5 mg of polymer particles in 1 
mL of DCM and then 3-4 mL of pbs was added. These replicates were incubated for 24 hrs in 
the incubator shaker at 37 0 C and then the supernatant was withdrawn. The concentration of 
drug was measured in the supernatant by measuring the absorbance in UV Spectrophotometer 
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at 269 nm for fluorouracil and 234 nm for metformin. This absorbance gave the corresponding 
concentration and the total amount was calculated. 
Encapsulation efficiency of the 5-FU microsphere delivery system. The encapsulation efficiency 
(EE) was calculated using the formula as below: 
       
   
     
         
 
 
3. RELEASE PROFILE 
In vitro release- The release tests were performed at 37˚C. Microspheres (5 mg) weighed were 
re-suspended in 10 ml PBS (pH 7.4) release medium. Then the samples were incubated in a 
simulating biological fluid incubator at 37˚C under a shaking rate of 150±10 rpm. The releas e 
medium was taken out, and then the supernatant of the samples was drawn (around 1 ml) for 
each day, and another 1 ml of fresh release medium was then placed. The concentration of the 
5-FU and Metformin was measured using UV Spectrophotometer. Average and standard 
deviation of the data were obtained from three replicates of the same sample. 
4. SHAPE AND MORPHOLOGY 
Analysis for shape and morphology of all samples of nanoparticles was done with SEM 
(Scanning Electron Microscopy). 
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Chapter 4 
RESULTS AND DISCUSSION 
 
4.1. Development of Standard plots  
EXPERIMENTAL CONDITIONS- According to the solubility characteristics of drugs, 
phosphate buffer pH 7.4 was selected as solvent for analysis. From the UV scanning of both the 
drugs, 234nm and 269nm were the wavelengths selected for estimation of metformin and 5 
Fluorouracil respectively. 
PREPARATION OF STOCK SOLUTIONS- 
5 FU and Metformin 10 mg each were accurately weighed and dissolved separately in phosphate 
buffer pH 7.4. Final volume was adjusted to 100ml with phosphate buffer pH 7.4 to get a 
concentration of 100µg/ml. 1ml of each from the above prepared solutions were further 
separately diluted to 10ml to get a concentration of 10µg/ml of each 5 FU and Metformin. 
These were used as stock solutions. 
WAVELENGTH SELECTION- The above prepared stock solutions of 5 FU and Metformin 
were scanned in the range of 200-400nm to determine the wavelength of maximum absorption 
for both the drugs. 5 FU showed absorption maxima at 269nm whereas Metformin showed at 
234 nm. 
The standard curves for both the drugs are depicted below. 
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OPTIMUM PARAMETERS 
 
PARAMETERS 5 FLUOROURACIL METFORMIN 
ʎ max (nm) 269 nm 234 nm 
Min conc (ug/mL) 2 2 
Max conc (ug/mL) 10 12 
Equation y = 0.0476x + 0.0238 y = 0.0798x + 0.0209 
Corelation cofficient R2 = 0.983 R2 = 0.9991 
 
 
Table 4.1.1 optimum parameters for standard plot 
y = 0.0476x + 0.0238 
R² = 0.983 
at 269 nm 
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Figure 4.1.2. Standard curve for 5 FU 
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4.2. OPTIMIZATION OF PROCESS PARAMETERS  
FOR W/O/W DOUBLE EMULSION TECHNIQUE 
The polymer concentration and the pva concentration along with other formulation variables 
were optimised by running trials with alternate parameters and it was found that the best 
results were derived when 2.5 % polymer concentration and 2.5 % of PVA was used. The ratio 
of drug is to polymer also plays a crucial role in the encapsulation of drug in the polymer 
particles. Size, on the other hand can be tuned by homogenizing or sonicating the emulsion at 
primary or secondary stage. It was observed that the speed of homogenization can affect the size 
of particles to a great extent. And then the final parameters were decided by which final batches 
of particles were prepared. Details of formulation variables are summarized in the table 4.2.1. 
Figure 4.1.1 Standard curve for Metformin 
y = 0.0798x + 0.0209 
R² = 0.9991 
at 234 nm 
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Table 4.2.1 Optimization of process parameters 
SN Primary Emulsion Secondary Emulsion Lyophilized 
Avg. 
Particle 
Size (um) 
Encapsulation(%) 
 
DRUG 
Con. 
(w/v)% 
PLGA 
Con. 
(w/v)% 
Homogenization 
Speed (RPM) & 
Time 
PVA 
Con. 
(w/v)% 
Homogenization 
Speed (RPM) 
and Time 
 
Y/N   
1 2.5 2.5 12500, 20 Sec. 0.25 8000, 10 Sec. N 1.0-2.5 
 
2 2.5 2.5 12000, 10 Sec 0.185 12000, 45 Sec N 1.0-2.0 
 
3 2.5 2.5 12000, 20 Sec 0.25 12000, 5 min. Y 1.0-2.0 
 
4 2.5 2.5 12000, 20 Sec 0.25 12000, 5 min. N 1.5-2.0 
 
5 2.5 2.5 12000, 20 Sec. 0.25 20000, 5 Min. N 0.5-2.0 
 
6 2.5 2.5 12000, 20 Sec. 0.25 30000, 5 Min. Y 1.0-1.5 
 
7 2.5 2.5 12000, 20 Sec. 0.25 30000, 5 Min. N 0.5-1.5 
 
8 5 2.5 Son. - 10 Sec.* 3 0.25 Son.- 10Sec.*3 N 1.0-2.0 17.71 
9 10 2.5 Son. - 10 Sec.* 3 2.5 
Son. - 10 Sec.* 
3 
N 1.0-2.0 2.97 
10 2.5 2.5 20000, 1 Min. 2.5 18000, 5 min. N 0.5-1.5 8.01 
11 2.5 2.5 20000, 1 Min. 2.5 12000, 5 Min. Y 1.0-1.5 25.88 
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4.3. PARTICLE SIZE ANALYSIS 
BY MICROSCOPY 
Particle size analysis was done by DLS and microscopy where slides of different batches were 
prepared by suspending the nanoparticles in water and then smearing on the slide. Respective 
slides were observed and the size measurement was done on Carl Ziess fluorescent microscope. 
fig 4.3.1 shows the size distribution of batches prepared by W/O/W and fig 4.3.0 shows the size 
distribution of batches prepared by W/O/O method. The size of particles lie in the range of 0.5 
um to 2.5 um and average size for W/O/O was 900 nm and 765 nm for W/O/O. fig. shows the 
images acquired from the microscope. 
 
figure 4.3.0: Particle size distribution of metformin nanoparticles prepared by w/o/o 
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figure 4.3.1: Particle size distribution of metformin nanoparticles  prepared by w/o/w 
BY DLS- 
The polydispersity index and average size of particles were determined by dynamic light 
scattering and the results are summarized in the table 4.3.1  
Table 4.3.1: Data obtained from DLS 
Technique % Loading Polydispersity Index Average Diameter 
(nm) 
W/0/W 1 0.337 847 
W/O/O 1 0.264 634 
W/O/W With SGnps 1 0.453 1858 
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and fig (4.3.2, 4.3.3, 4.3.4) depicts the details obtained by DLS for W/o/o, W/o/W and Sgnp 
respectively.  
 
 
Figure 4.3.2: DLS data of W/O/O Fluorouracil nanoparticles 
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Figure 4.3.3: DLS data of W/O/W Fluorouracil nanoparticles 
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Figure 4.3.4: DLS data of W/O/W with Fluorouracil SgNp nanoparticles 
 
The polydispersity index as we can see is 0.337 and 0.453 which indicates a optimum 
distribution of particles and the extent of homogenity in the size of particles. 
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SEM IMAGES OF MICROPARTICLES  
Sem image of microparticles were acquired at different magnifications and 12.00 kv to 
see the porosity and morphology of particles. The particles prepared by W/o/W are not 
porous and are little bigger in size as sgnp's are incorporated in them. One of such 
image is given below. 
 
Figure 4.3.5 Sem Image of 5 FU Sgnp at 25.00 kx 
 
 
4.4 COMPARISON OF ENCAPSULATION EFFICIENCY 
Table 4.4.1, 4.4.2 and 4.4.3 shows the comparison between encapsulation efficiency of 
conventional method and method in which sgnp's are incorporated. 
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Table 4.4.1: Comparison of EE of 1 % loading with different loading 
TECHNIQUE % LOADING % EE STD DEV 
W/O/W 1 4.06 1.2 
SG+ W/O/W 1 64.33 3.5 
W/O/O 1 88 3 
SG+ W/O/O 1 60 3 
 
As we can clearly see that sugar glass nanoparticles have higher encapsulation efficiency, no 
matter which technique is followed. As in 1 % loading, the EE of particles by conventional 
w/o/w technique is 4.06 and that of sugar glass is 64.33 %. 
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Table 4.4.2 ENCAPSULATION EFFICIENCY OF 5 % LOADING 
TECHNIQUE  % LOADING  % EE  STD DEV  
W/O/W  5  2.01  0.215  
SG+ W/O/W  5  55.33  3.5  
W/O/O  5  48.66  3.7  
SG+ W/O/O  5  50.66  3  
 
Table: 4.4.3: ENCAPSULATION EFFICIENCY OF 1 % LOADING of METFORMIN 
TECHNIQUE  % LOADING  % EE  STD DEV  
W/O/W  1  2.36  0.37  
SG+ W/O/W  1  33  0.5  
W/O/O  1  44.33  3.05  
SG+ W/O/O  1  56  1.7  
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4.5 RELEASE PROFILE STUDY 
Figure 4.5.1 shows the release profile of fluorouracil particles prepared by w/o/w, as we can see 
there is a 76 % of burst release in 1 hour which is very high. Contrary to this, the release in 1 
hour for same loading with sugar glass nanoparticles of fluorouracil is only 22 %, shown in fig. 
4.5.2. 
 
 
 
 
Figure 4.5.1 Release profile of 5 FU NP prepared by W/O/W 
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Figure 4.5.3: Release profile of 5 FU NP 1 % prepared by W/O/W 
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Figure 4.5.2 Release profile of 5 FU SgNp prepared by W/O/W 
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Figure 4.5.4: Release profile of 5 FU SgNP 1 % prepared by W/O/W 
 
The above depicted figures (4.5.3 and 4.5.4) shows the release profile of 1 % loading of 5 FU by 
conventional method and by incorporation of sgnps in the same technique. There was burst 
release of 67 % in conventional method, while only 22 % was released in 1 hour from sgnp 
system. 
Similar comparisons are done between respective loadings and the graphs of release profile has 
been plotted. (fig 4.5.5 and 4.5.6) shows the comparison between release profiles of sgnp and np 
prepared by conventional technique for 5 % and 1 % loading respectively. 
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Figure 4.5.5 Release profile of 5 FU SgNp and np made by W/O/O technique. 
 
 
Figure 4.5.6 Release profile of 5 FU SgNp and np made by W/O/O technique.   
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Figure 4.5.7 and 4.5.8 represents the graph for release profile evaluated for metformin 
nanoparticles and sgnp of metformin with 1 % loading and prepared by w/o/w method 
 
 
Figure 4.5.7: Release profile of Metformin Np 1 % prepared by W/O/W 
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Figure 4.5.8: Release profile of Metformin SgNP 1 % prepared by W/O/W 
 
 
It can be clearly concluded that the release profile for sgnp is controlled and has shown an 
acceptable minimal burst release of 20 %- 30 %. A good encapsulation of hydrophilic is 
demonstrated and thus this technique can be used for future delivery systems for hydrophilic 
drugs. The details of the experiments carried out for demonstration of release and encapsulation 
efficiency can be found in previous chapters. 
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SUMMARY 
The novel approach used here gave better encapsulation efficiency unlike conventional methods. 
This method can also be called as solid in oil in oil or solid in oil in water. The absence of burst 
release may be due to the longer path that the drug has to travel in polymer particles and also 
the system has shown controlled release pattern which is attributed to the degradability of 
polymer. We have also evaluated both the conventional and modified water in oil in oil, double 
emulsion method using sugar glass nano particles as an encapsulant. There was a initial burst 
release of 20-35 % and then it followed sustained release similar to bimodal release pattern 
unlike other where it was around 90 %. Also the size of particles was in range of 300-900 nm. 
Encapsulation of the drug increased to 64.33 % when using sugar glass system unlike W/O/W 
double emulsion method where the encapsulation was around 4 %. It is concluded that this new 
modified double emulsion technique incorporating sugar glass particles of drug is better and 
advantageous than conventional double emulsion technique in terms of size, shape, release 
profile and encapsulation efficiency. This novel approach can be very useful in solving the 
problems associated with delivery of hydrophilic drug. 
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